OncLive TV

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

John Zalcberg, ​PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.

Carlo Visco, MD, discusses the next steps for the international, retrospective MANTLE-FIRST trial in patients with relapsed/refractory mantle cell lymphoma.

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Quoc-Dien Trinh, MD, discusses current strategies on the treatment of patients with high-risk prostate cancer during the COVID-19 crisis.

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Paul L. Nguyen, MD, discusses the utility of adding a brachytherapy boost to radiation therapy in the ASCENDE-RT trial.

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Omar Alkharabsheh, MD, discusses novel agents under exploration in the field of myelofibrosis.

Allyson Ocean, ​MD, discusses the need for additional second-line therapies in metastatic pancreatic cancer. 

Caroline Farrington, PhD, ​discusses the importance of patient advocacy in colorectal cancer.

Alexander N. Shoushtari, MD, discusses the role of nivolumab and ipilimumab in mucosal melanoma. 

Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses the current treatment landscape in ​relapsed/refractory indolent non-Hodgkin lymphoma.

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.